About Biological E
Biological E is a company based in Hyderabad (India) founded in 1953 by Datla Venkata Krishnam Raju.. The company has 1 employees as of September 20, 2024. Biological E has completed 2 acquisitions, including Akorn and Akorn India. Biological E offers products and services including CORBEVAX, Hepatitis B Vaccine, Pentavalent Vaccine, and Typhoid Conjugate Vaccine. Biological E operates in a competitive market with competitors including Vir Biotechnology, Vaxcyte, Cidara Therapeutics, Freeline and Altimmune, among others.
- Headquarter Hyderabad, India
- Employees 1 as on 20 Sep, 2024
- Founders Datla Venkata Krishnam Raju
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Biological E. Limited
- Jurisdiction Andhra Pradesh, Telangana, India
-
Annual Revenue
$316.36 M (USD)-29.92as on Mar 31, 2024
-
Net Profit
$94.65 M (USD)-15.09as on Mar 31, 2024
-
EBITDA
$78.24 M (USD)-45.74as on Mar 31, 2024
-
Latest Funding Round
$50 M (USD), Grant
Oct 24, 2021
-
Investors
International Finance Corporation
& 1 more
-
Employee Count
1
as on Sep 20, 2024
-
Investments & Acquisitions
Akorn
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biological E
Biological E offers a comprehensive portfolio of products and services, including CORBEVAX, Hepatitis B Vaccine, Pentavalent Vaccine, and Typhoid Conjugate Vaccine. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Vaccine for preventing SARS-CoV2 infections.
Vaccine to prevent Hepatitis B disease.
Combined vaccine for diphtheria, tetanus, pertussis, hepatitis B, and Hib.
Vaccine against typhoid fever in children and adults.
Unlock access to complete
Funding Insights of Biological E
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $50.0M
-
First Round
First Round
(18 Dec 2020)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2021 | Amount | Grant - Biological E | Valuation |
investors |
|
| Dec, 2020 | Amount | Debt – Conventional - Biological E | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Biological E
Biological E has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include International Finance Corporation and DFC. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency supporting the development of SMEs
|
Founded Year | Domain | Location | |
|
IFC is focused on private sector development in emerging markets.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Biological E
Biological E has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Akorn and Akorn India. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Sterile pharmaceuticals are developed, manufactured, and marketed by Akorn India.
|
2011 | ||||
|
Injectable and ophthalmic pharmaceutical products were manufactured across therapeutic areas.
|
1948 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Biological E
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Biological E Comparisons
Competitors of Biological E
Biological E operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Vir Biotechnology, Vaxcyte, Cidara Therapeutics, Freeline and Altimmune, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| domain | founded_year | HQ Location |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Prophylactic vaccines for infectious diseases are developed and advanced.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Biological E
Frequently Asked Questions about Biological E
When was Biological E founded?
Biological E was founded in 1953 and raised its 1st funding round 67 years after it was founded.
Where is Biological E located?
Biological E is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Who is the current CEO of Biological E?
Mahima Datla is the current CEO of Biological E.
How many employees does Biological E have?
As of Sep 20, 2024, the latest employee count at Biological E is 1.
What is the annual revenue of Biological E?
Annual revenue of Biological E is $316.36M as on Mar 31, 2024.
What does Biological E do?
Biological E was founded in 1953 in Hyderabad, India, as a biopharmaceutical company. Innovative vaccines, branded generics, and novel therapeutics are developed, manufactured, and marketed globally. The product pipeline encompasses pneumococcal conjugate vaccine, Hib vaccine, poliomyelitis vaccine, COVID-19 vaccine, hepatitis A vaccine, and measles vaccine. Operations are centered on addressing various infectious diseases through research and production.
Who are the top competitors of Biological E?
Biological E's top competitors include Vaxcyte, Serum Institute of India and RedHill Biopharma.
What products or services does Biological E offer?
Biological E offers CORBEVAX, Hepatitis B Vaccine, Pentavalent Vaccine, and Typhoid Conjugate Vaccine.
How many acquisitions has Biological E made?
Biological E has made 2 acquisitions, including Akorn, and Akorn India.
Who are Biological E's investors?
Biological E has 2 investors. Key investors include International Finance Corporation, and DFC.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.